TrovaGene (NASDAQ:TROV)‘s stock had its “buy” rating reaffirmed by investment analysts at Aegis in a note issued to investors on Tuesday, Analyst Ratings.Net reports. They currently have a $14.00 price objective on the stock. Aegis’ price target indicates a potential upside of 94.99% from the stock’s previous close.
Separately, analysts at Cantor Fitzgerald initiated coverage on shares of TrovaGene (NASDAQ:TROV) in a research note to investors on Monday, July 15th. They set a “buy” rating and a $10.00 price target on the stock.
TrovaGene (NASDAQ:TROV) traded up 13.93% on Tuesday, hitting $8.18. 338,520 shares of the company’s stock traded hands. TrovaGene has a 52 week low of $3.35 and a 52 week high of $10.27. The stock’s 50-day moving average is $7.87 and its 200-day moving average is $7.00. The company’s market cap is $154.2 million.
TrovaGene (NASDAQ:TROV) last released its earnings data on Wednesday, August 14th. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.15) by $0.19. On average, analysts predict that TrovaGene will post $-0.84 earnings per share for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.